Texas Children's Cancer and Hematology Centers
Welcome,         Profile    Billing    Logout  
 30 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zage, Peter
NCT03611595: Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting
1
18
US
Cabozantinib, CABOMETYX, 13-cis-retinoic acid, isotretinoin
Peter Zage, Exelixis
Solid Tumor
08/25
08/26
Rawwas, Jawhar
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
Foster, Jennifer H
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Recruiting
2
60
US
131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat
Jubilant DraxImage Inc.
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
12/23
04/25
NETTER-P, NCT04711135 / 2020-002951-39: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Active, not recruiting
2
11
Europe, US
Lutetium [177Lu] oxodotreotide/dotatate, Lutathera
Advanced Accelerator Applications
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
03/24
05/29
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
09/22
12/24
NCT04239092: 9-ING-41 in Pediatric Patients with Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
NCT05610891: Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Recruiting
1
50
Canada, US
CLR 131, iopofosine I 131
Cellectar Biosciences, Inc., National Cancer Institute (NCI)
High-Grade Glioma
05/26
09/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
Fontaine, Cara-Lee
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31

Download Options